# K130174: Dvtcare CA5

- Pathway: 510(k) (Traditional)
- Applicant: Ossur Americas, Inc.
- Decided: May 2, 2013 after 98 days
- Product code: JOW (Sleeve, Limb, Compressible)
- Device class: 2
- Regulation: 21 CFR 870.5800
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 4 generations back to K915638 (1992). 15 ancestors in all.
2 later devices descend from it; 1 cites it directly.
0 of 18 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K061125: Dvtcare CA5, Doctors Orders (2006) Summary page 1.
- K103187: Tripleplay-VT Vascular Therapy System, Wildcat Medical, Inc. (2011) Summary page 1.

## Most influential descendants
- K200285: VenaOne (2020), 1 descendant of its own
- K212731: Circul8 Pro (2021), 0 descendants of its own

## Indications for use
The DVTCare CA5 is intended to be a portable system that is prescribed by healthcare professionals to help prevent the onset of DVT in patients, by stimulating blood flow in the legs (simulating muscle contractions). Furthermore, the unit can be used as an aid in the prophylaxis for DVT by persons traveling, or those expecting to be stationary for long periods of time (> 4 hours). This device can also be used to: aid in the prevention of DVT, enhance blood circulation, diminish post-operative pain and swelling, reduce wound healing time, and aid in the treatment and healing of: stasis dermatitis, venous stasis ulcers, arterial and diabetic leg ulcers, chronic venous insufficiency, and reduction of edema in the lower limbs.

Source page: https://510kreport.com/device/K130174
Methodology: https://510kreport.com/methodology